Navigation Links
MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
Date:7/1/2008

clinical trials for psychiatric drugs; we will now be able to bring this same new paradigm to bear in other areas of critical medical need, such as the development of new treatments for Alzheimer's disease and the assessment of the risk of suicidality for all classes of drugs."

The former FDA Deputy Commissioner for Medical and Scientific Affairs, Scott Gottlieb, MD, a member of MedAvante's Board of Directors, commented, "The cost of conducting trials to treat neurological and psychiatric disorders has been increasing rapidly in recent years in large part due to the approaches industry has been using to measure patient response. Larger numbers of patients are being enrolled in psychiatric trials simply because outdated approaches to drug development require more patients to be exposed to an experimental drug to see whether it's working." He continued, "MedAvante has pioneered an approach that offers one of the most effective solutions to improving the efficiency and reliability of psychiatric drug development, enabling new treatments to be assessed more efficiently for safety and effectiveness and potentially reach patients sooner and at lower cost."

Andrew Fink, Managing Director of Trevi Health Ventures, noted, "MedAvante's solution solves the critical problem of enhancing precision and reliability in central nervous system trials head-on. This capital infusion will enable the company to meet the rapidly expanding demand for more accurate psychiatric assessment. Importantly, MedAvante has demonstrated the ability to deliver centralized ratings with the operational precision and scalability needed to expand globally."

Walter Greenblatt & Associates served as MedAvante's exclusive financial advisor in the transaction.

About MedAvante

MedAvante has pioneered and commercialized a solution that addresses one of the global pharmaceutical industry's most intractable problems: the high rate of uninformative or failed studies. MedAvante p
'/>"/>

SOURCE MedAvante, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 JH ... California showroom located in Irvine. JH Technologies, a ... imaging systems, recently announced an expanded partnership with Leica ... leading microscopes and image analysis solutions will be featured ... 2nd. The new showroom facility is located within ...
(Date:9/17/2014)... -- Hussey Copper , a leader in copper ... announces Gilmour Academy Ice Arena,s conversion of more than ... touch surface to help protect against bacteria.  MD-Cu 29 ... kills greater than 99.9% of MRSA, E-coli and other ... , Innovative Gilmour Academy prepares ...
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
(Date:9/17/2014)... September 17, 2014 The Pistoia ... to lowering the barriers to innovation in life ... appointment of Carmen Nitsche as Executive Director Business ... expand its global reach. , Carmen joins the ... President, Corporate Development. At Accelrys, she managed various ...
Breaking Biology Technology:JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... Dec. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... and,medical device company, is scheduled to participate in ... December 12-13 in New York, NY., Tom ... in a panel discussion on Thursday, December 13, ...
... Raven,biotechnologies, inc., a privately held company focused on ... today announced that,Wyeth Pharmaceuticals, a division of Wyeth ... extend its evaluation of selected Raven MAb antibodies. ... payment., Under an agreement announced in January ...
... N.J., Dec. 5 Schering-Plough,Corporation (NYSE: SGP ... last,night with three top pharmaceutical industry awards: Large ... Year, and Executive of the Year for,Fred Hassan, ... are designed to recognize excellence and achievement,within the ...
Cached Biology Technology:Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2Schering-Plough Wins Three of Scrip's Top Pharma Industry Awards 2
(Date:9/16/2014)... 2014)The North American Menopause Society (NAMS) has published ... of midlife womenon everything from hot flashes to ... Menopause Society Recommendations for Clinical Care of Midlife ... journal Menopause . This is the first, ... of midlife women freely available to all clinicians ...
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... High school biology taught us that we inherit certain ... if you could change how these genes play out ... your diet? That,s exactly what a team of ... have proposed through their research of epigenetics research. ... by chemically modifying DNA and histone proteins, which prevent ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... 3 issue of Nature, Johns Hopkins researchers report that ... come together to turn the liver into a sugar-producing ... of sugar is a damaging problem in people with ... future drugs to fight the disease, the researchers say. ...
... Mayo Clinic researchers and conducted by the North Central Cancer ... for an incurable form of recurrent brain cancer slowed tumor ... who tried it. The same research team also developed a ... to this treatment. , Mayo researchers will present these findings ...
... by camouflage in the same way that humans are deceived, ... idea that bold contrasting colours help to break-up the body's ... as the First World War. And in biology this idea ... insects such as moths conceal themselves from predators, shaping the ...
Cached Biology News:Computational verification of protein-protein interactions by orthologous co-expression 2Computational verification of protein-protein interactions by orthologous co-expression 3'Smart drug' targets deadly brain cancer 2'Smart drug' targets deadly brain cancer 3
37-1A9...
sPLA2-XII Human, Rabbit Polyconal Antibody Anti-Human sPLA2-XII Antibody was raised in rabbits against Human sPLA2-XII His-Tagged Fusion Protein Antigen: The recombinant human protein sPLA-XII...
...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Biology Products: